551 results on '"Gumus, Mahmut"'
Search Results
2. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
3. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial
4. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
5. The results of adding immunotherapy to chemotherapy in patients with small cell lung cancer: Registurk-Lung study—Real-world data.
6. Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.
7. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC
8. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.
9. LUNGBANK: A Novel Biorepository Strategy Tailored for Comprehensive Multi-Omics Analysis and P-Medicine Applications in Lung Cancer
10. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
11. Nutritional Aspect of Cancer Care in Medical Oncology Patients
12. Is Clinical Risk Score a Useful Predictive Marker of Early Recurrence Among Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors?
13. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
14. #1121 KEYNOTE-826: final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
15. Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial
16. Changes in Sexual Function of Patients with Cancer in Turkey
17. The Prognostic Utility of the Metastatic Lymph Node Ratio and the Number of Regional Lymph Nodes Removed from Patients with Small Bowel Adenocarcinomas
18. Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.
19. Prognostic Significance of C-Reactive Protein and Neutrophil-Lymphocyte Ratio in Lung Adenocarcinoma Patients.
20. KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer.
21. Major and minor salivary gland cancers: A multicenter retrospective study
22. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study
23. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
24. Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
25. Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors
26. Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology
27. Abstract CT554: Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced squamous (sq) non-small-cell lung cancer (NSCLC): Sub-analysis from phase 3 RATIONALE-303 randomized clinical study
28. Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) stage IV colorectal cancer (CRC).
29. Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826.
30. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wi̇ld-type patients treated with biologics second-line mCRC.
31. Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).
32. Primary renal carcinoid: Treatment and prognosis
33. Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection
34. Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma
35. Treatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian Society of Medical Oncology
36. The changing of serum vitamin B12 and homocysteine levels after gastrectomy in patients with gastric cancer: do they associate with clinicopathological factors?
37. Surgical, pathological and clinical features of advanced collorectal cancers with metastasectomy. Onco-Colon Turkey Registry real-life data
38. Metastatic renal hemangiopericytoma: A rare case report
39. First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.
40. Psychological Impacts of COVID-19 Pandemic in Cancer Patients on Active Treatment
41. Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology
42. Where Should Enzalutamide Be in The Metastatic Castration Resistant Prostate Cancer (mCRPC): A Multi-center Study.
43. Fasting plasma glucose and body mass index as predictors of neoadjuvant chemotherapy response in breast cancer.
44. Induction Chemotherapy and Chemoradiation Therapy for Inoperable Locally Advanced Non–Small-Cell Lung Cancer: A Single-Institution Review of Two Different Regimens
45. Second Line Treatment Choice in Extensive Small Lung Cancer.
46. The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer
47. The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer
48. Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer
49. Clinical importance of phosphatase of regenerating liver-3 expression in breast cancer
50. Additional file 1 of Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.